The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Rieder, Florian ^a,b   Siegmund, Britta ^a,c   Bundschuh, Daniela S ^d   Lehr, Hans Anton ^e   Endres, Stefan ^a   Eigler, Andreas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Takeda Pharmaceuticals International GmbH   (Switzerland)

^e UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; PUMAFENTRINE; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE LEVEL;

AMINOPYRIDINES; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BENZAMIDES; COLITIS; COLON; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; INTESTINAL MUCOSA; LECTINS, C-TYPE; MICE; NAPHTHYRIDINES; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874528469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056867     Document Type: Article

References (40)

1. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT, (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709.
2. Podolsky DK, (2002) Inflammatory bowel disease. N Engl J Med 347: 417-429.
3. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117: 761-769.
4. Sandborn WJ, Hanauer SB, (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5: 119-133.
5. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.
6. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
7. Giembycz MA (2005) Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 326-333; discussion 340-321.
8. Semmler J, Wachtel H, Endres S, (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 15: 409-413.
9. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, et al. (2000) Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 292: 22-30.
10. Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, et al. (2003) The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 305: 549-556.
11. Banner KH, Trevethick MA, (2004) PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 25: 430-436.
12. Sturgess I, Searle GF, (1990) The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality. Br J Clin Pharmacol 29: 369-370.
13. Torphy TJ, (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157: 351-370.
14. Bielekova B, Lincoln A, McFarland H, Martin R, (2000) Therapeutic potential of phosphodiesterase-4 and-3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164: 1117-1124.
15. Hatzelmann A, Schudt C, (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279.
16. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, et al. (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297: 280-290.
17. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, et al. (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695-703.
18. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, et al. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694.
19. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S,et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256.
20. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, et al. (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62: 1081-1087.
21. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, et al. (2005) Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366: 563-571.
22. Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, et al. (2008) Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J 31: 599-610.
23. Elson CO, Sartor RB, Tennyson GS, Riddell RH, (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367.
24. Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, et al. (2001) Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 296: 99-105.
25. Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, et al. (2003) Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 307: 349-355.
26. Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W (1992) In vitro assays for mouse lymphocyte function. Current Protocols in Immunology: 3.1.3-3.1.5, John Wiley & Sons, Inc. New York.
27. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, Tanikawa K, (1998) Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand J Gastroenterol 33: 435-440.
28. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, et al. (1997) Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358.
29. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, et al. (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38: 1722-1734.
30. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1: 244-248.
31. Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L, (1997) Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol 108: 415-419.
32. Banner KH, Press NJ, (2009) Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 157: 892-906.
33. Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, et al. (2006) Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 316: 940-945.
34. Ichikawa H, Okamoto S, Kamada N, Nagamoto H, Kitazume MT, et al. (2008) Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. Inflamm Bowel Dis 14: 1483-1490.
35. Diaz-Granados N, Howe K, Lu J, McKay DM, (2000) Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156: 2169-2177.
36. Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, et al. (2007) A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132: 76-86.
37. Cooper HS, Murthy SN, Shah RS, Sedergran DJ, (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
38. Ziegler SF, Levin SD, Johnson L, Copeland NG, Gilbert DJ, et al. (1994) The mouse CD69 gene. Structure, expression, and mapping to the NK gene complex. J Immunol 152: 1228-1236.
39. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S, (1995) Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 25: 147-153.
40. Ziegler-Heitbrock HW, Blumenstein M, Kafferlein E, Kieper D, Petersmann I, et al. (1992) In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 75: 264-268.